Advertisement
News
Advertisement

FDA review halts Alkermes trading

Thu, 09/16/2010 - 5:33am
Mass High Tech: The Journal of New England Technology

Pharmaceutical company Alkermes Inc. (Nasdaq: ALKS) reported this morning that Nasdaq has halted trading of Alkermes’ common stock because of an expedited review by a U.S. Food and Drug Administration.

In a press release, Waltham-based Alkermes said the Psychopharmacologic Drugs Advisory Committee appointed by the FDA meets today to review the company’s supplemental New Drug Application (sDNA) for Vivitrol (naltrexone for extended-release injectable suspension) for opioid dependence.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading